Cardiovascular
Cardiovascular
Womens Health
Women's Health
two kidneys
Nephrology
Oncology
Oncology
Ophthalmology
Ophthalmology
Respiratory
Respiratory
Bayer for ProfessionalsYour Resource Portal
EYLEA General
nAMD
DMO

TREAT WITH A KNOWN MOLECULE AND SAFETY PROFILE

The reassurance of treating your patients with the tried-and-trusted aflibercept molecule
1–5

In PULSAR and PHOTON, EYLEA 8 mg demonstrated a safety profile consistent with EYLEA 2 mg from baseline through Week 96:1–5*

EYLEA 8 mg Safety Profile

*EYLEA (aflibercept) 2 mg was dosed at fixed Q8 intervals after 3 (nAMD) or 5 (DMO) initial monthly injections.4,6

PHOTON safety

Adverse events in patients receiving EYLEA 8 mg were consistent with EYLEA 2 mg
2,4

PHOTON: most frequent AEs through Week 48

2Q8

8Q12

8Q16

All 8 mg

N (SAF)

167

328

163

491

Patients with ≥1 AE (%)*

27.5%

31.7%

29.4%

31.0%

   Cataract

1.2%

1.5%

4.9%

2.6%

   Conjunctival haemorrhage

3.6%

4.3%

3.7%

4.1%

   Intraocular pressure increased

3.6%

2.1%

0.6%

1.6%

   Punctate keratitis

0.6%

1.5%

3.7%

2.2%

   Retinal haemorrhage

0.6%

0%

3.7%

1.2%

   Vitreous floaters

2.4%

4.9%

1.8%

3.9%

   APTC events†

3.6%

2.4%

4.3%

3.1%

   Hypertension events†

12.0%

11.0%

14.1%

12.0%

   Non-ocular SAEs†

15.6%

15.9%

13.5%

15.1%

   Deaths‡

2.4%

2.7%

1.8%

2.4%

Adapted from Do D. 2023.

 

*Any ocular treatment-emergent AE in the study eye.2
†Treatment-emergent events.2
‡All events.2

Dosing

Discover proactive dosing in nAMD and DMO

MoA

Discover more about the MoA of EYLEA 8 mg

nAMD Safety Profile

Explore the safety profile of EYLEA 8 mg in nAMD

Abbreviations

2Q8, 2 mg every 8 weeks. 8Q12, 8 mg every 12 weeks. 8Q16, 8 mg every 16 weeks. AE, adverse event. APTC, Anti-Platelet Trialists’ Collaboration. DMO, diabetic macular oedema. IOI, intraocular inflammation. IOP, intraocular pressure. MoA, mechanism of action. nAMD, neovascular (wet) age-related macular degeneration. Q8, every 8 weeks. SAE, serious adverse event. SAF, safety analysis set. TEAE, treatment-emergent adverse event.

References

  1. Korobelnik J-F. Intravitreal aflibercept 8 mg injection in patients with neovascular age-related macular degeneration: 48-week results from the Phase 3 PULSAR trial. Retina Society. 2–5 November 2022. Pasadena, USA. Oral presentation.
  2. Do D. Aflibercept 8 mg for diabetic macular edema: 48-week results from the Phase 2/3 PHOTON trial. ARVO. 23–27 April 2023. Palo Alto, USA. Oral presentation.
  3. Korobelnik J-F. Aflibercept 8 mg in patients with neovascular age-related macular degeneration: Phase 3 PULSAR trial 96-week results. AAO. 3–6 November 2023. San Francisco, USA. Oral presentation.
  4. Wykoff CC. Aflibercept 8 mg for diabetic macular edema: 96-week results from the Phase 2/3 PHOTON trial. EURETINA. 5–8 October 2023. Amsterdam, The Netherlands. Oral presentation.
  5. EYLEA® 114.3 mg/mL Summary of Product Characteristics.
  6. Lanzetta P, et al. Intravitreal aflibercept 8 mg injection in patients with neovascular age-related macular degeneration: 60-week and 96-week results from the Phase 3 PULSAR trial. EURETINA. 5–8 October 2023. Amsterdam, The Netherlands. Oral presentation.

PP-EYL-GB-2328 | August 2024

First Page
DMO